Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules

Today's cyclodextrin, ,

This is a great example of using CDs in a downstream processing method to produce bispecific antigen-binding molecule. In Amgen‘s invention, β-CD is applied in the process either in a buffer applied in the filtration step or added to the filtration pool after the UF/DF filtration step to keep the product in a non-aggregated form.
Yan Wang; Nicholas Marchand; Robert Brake; Maria Perry; Ashish Sharma; Eugene Sun

See the full patent here.

Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance

Today's cyclodextrin, ,

Antibody-drug conjugates (ADCs) have begun to fulfill their promise as targeted cancer therapeutics with ten clinical approvals to date. Recently the role that linker-payload reagent design has on the properties of ADCs has been highlighted as an important consideration for developers. In this paper from Abzena, the effect of incorporating hydrophilic macrocycles like cyclodextrin into reagent structures on the in vitro and in vivo behavior of ADCs.

Nick Evans, Ruslan Grygorash, Nicolas Camper, Mark Frigerio, Matthew Bird et al

See the full article here

Methyl-BCD is used in antibody-drug conjugate

Today's cyclodextrin, ,

An interesting application is highlighted in the patent of RemeGen荣昌生物: methyl-BCD is used in antibody-drug conjugate formulations where the primary benefit is that ADC dose can be lowered (due to higher efficacy), which leads to mitigating safety concerns lowering costs, and patient treatment costs. Fascinating, huh? (Figure: Araris Biotech AG)

See the full patent on Espacenet.